At a glance
ClinicalIndex Comparison Record- ✓Candidate for elective or urgent PCI with intended coronary stenting
- ✓Age 18–75 years
- ✕Acute ST-elevation myocardial infarction (STEMI) as indication for PCI
- ✕Oral anticoagulation therapy that cannot be safely discontinued
- ✕Cardiogenic shock or severe congestive heart failure
- ✕Active internal bleeding or history of bleeding diathesis
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Double-Blind, Randomized, Multicenter, Dose-Ranging Trial of CS-747 Compared With Clopidogrel in Subjects Undergoing Percutaneous Coronary Intervention
In Brief
A Phase 2 clinical trial evaluating Prasugrel (CS-747) and Clopidogrel for Cardiovascular Diseases and Heart Diseases. Completed, enrolled 905 participants across 2 sites in 2 countries.
Detailed Summary
The purpose of this study is to evaluate the effects of a drug known as CS-747 (also known as prasugrel) on subjects having a procedure called a percutaneous coronary intervention (also referred to as PCI) in which a doctor will attempt to open a blocked vessel (or vessels) in the heart using a catheter (a long thin tube) that has a small balloon on the end. In many cases, patients who have this procedure receive a stent, a small wire spring that helps keep the vessel open.
Study Details
Timeline
Interventions
Administered orally
Administered orally